BBIO — BridgeBio Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1743881 ·
Last close
$76.80
Market Cap
$14.96B
52W High
$93.42
52W Low
$62.50
ADV30
2,789,347
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 353,171,000 | 332,721,000 | -11,639,000 | -56,710,000 | 2,161,786,000 | 1,533,363,000 | 3,815,291,000 |
| Jun 2026 | 243,676,000 | 228,630,000 | -107,079,000 | -152,216,000 | 1,217,299,000 | 677,911,000 | 3,723,192,000 |
| Mar 2026 | 194,515,000 | 184,576,000 | -105,956,000 | -164,043,000 | 1,370,981,000 | 879,891,000 | 3,639,856,000 |
| Dec 2025 | 154,178,000 | 146,071,000 | -128,431,000 | -192,863,000 | 936,025,000 | 570,119,000 | 3,012,606,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-368,970,000
Investing CF
$-2,593,000
Financing CF
$1,261,955,000
CapEx
$-835,000
Dividends Paid
—
Buybacks
$-273,363,000
EPS Diluted TTM
$-3.04
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,194,163,000
Inventory
$59,718,000
Receivables
$375,089,000
ST Investments
$5,492,000
EBIT TTM
$-363,179,000
Pretax Income TTM
$-576,468,000
Interest Exp TTM
$213,289,000
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$945,539,968
EBITDA
$-348,361,984
Free Cash Flow
$-302,881,248
Enterprise Value
$17,390,876,672
Total Cash
$1,538,855,040
Total Debt
$3,378,097,920
Shares Out
194,800,782
Trailing EPS
$-3.03
Book Value
$-13.29
ROE
—
ROA
-14.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 502,076,000 | -502,064,000 | -724,931,000 | 936,025,000 | 3,012,606,000 | -2,086,610,000 | -445,910,000 |
| Dec 2024 | 221,902,000 | -577,368,000 | -535,762,000 | 919,338,000 | 2,376,950,000 | -1,467,904,000 | -520,726,000 |
| Dec 2023 | 9,303,000 | -599,444,000 | -643,202,000 | 546,380,000 | 1,888,915,000 | -1,354,257,000 | -527,720,000 |
| Dec 2022 | 77,648,000 | -468,437,000 | -481,183,000 | 623,036,000 | 1,867,960,000 | -1,254,617,000 | -419,494,000 |
TTM Snapshot
Revenues TTM
$713,069,000
NetIncome TTM
$-691,865,000
OpCashFlow TTM
—
Assets (Latest)
$1,217,299,000
Forward EPS
$-0.05
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $70.00 · spot: $78.01 · call volume: 578 · put volume: 1,212
Expected Move to 2027-01-15:
±$22.05
(28.27%) —
implied range
$55.96 –
$100.06
· ATM straddle on $77.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $15.45B | $240.71 | — |
| ELAN | Elanco Animal Health Inc | $12.92B | $25.85 | — |
| ASND | Ascendis Pharma A/S | $17.84B | $271.19 | — |
| RDY | DR REDDYS LABORATORIES LTD | $12.32B | $14.79 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.33B | $58.51 | — |
News headlines (Yahoo Finance, 1h cache)
BridgeBio Pharma (BBIO) Could Be 212% Overvalued After New Acoramidis Data
2026-11-19 05:13 · Yahoo
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
2026-11-11 12:30 · Yahoo
Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery
2026-11-09 14:31 · Yahoo
BridgeBio to Participate in November and December Investor Conferences
2026-11-09 12:30 · Yahoo
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:01 · Yahoo
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
2026-11-03 12:30 · Yahoo
Should You Invest $1,000 in BridgeBio Pharma Right Now?
2026-11-02 12:05 · Yahoo
What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?
2026-11-01 21:10 · Yahoo
BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says
2026-10-30 17:04 · Yahoo
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript
2026-10-30 14:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.